July 30, 2020
GE Healthcare to Distribute Osprey Medical’s Contrast-Reduction Technology in Europe and Other Regions
July 30, 2020—GE Healthcare and Osprey Medical Inc. announced a strategic alliance under which GE Healthcare will exclusively distribute Osprey’s product portfolio in Europe, Russia, the Middle East, Africa, Central Asia, and Turkey.
Under the 4-year agreement, GE Healthcare will commercialize Osprey’s DyeVert portfolio within these regions. As Osprey develops new products, GE Healthcare will be granted a right of first refusal to distribute and promote these products in these markets.
Osprey’s FDA-cleared technology is indicated for reducing patient contrast exposure. The DyeVert portfolio allows health care providers to monitor cumulative dye dose specific to each patient’s kidney function determined before the procedure. The devices reduce the amount of contrast that reaches the kidney by an average of 40% with no compromise in image quality.
According to the companies, Osprey’s DyeVert contrast minimization devices are complemented by GE Healthcare's range of iodinated x-ray contrast media to address acute kidney injury following interventional coronary angiograms in patients with chronic kidney disease.